GET DAILY SIGNALSThe Pennant Group (PNTG) Delivers Solid Q3 2026 Results with +32% Revenue Growth
Key Takeaways
- Third quarter 2026 revenue rose 32.0% year over year to $302.3 million, coming in ahead of consensus estimates near $299 million.
- GAAP diluted earnings per share (EPS) was $0.26, up 52.9% from $0.17 a year earlier, while adjusted diluted EPS of $0.35 was in line with consensus.
- Net income attributable to The Pennant Group grew 58.5% year over year to $9.6 million.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 42.4% to $24.7 million.
- Home Health and Hospice segment revenue rose 38.2% to $239.8 million, while Senior Living revenue increased 12.6% to $62.4 million despite softer occupancy.
- For more context on this ticker's latest developments, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- To discover AI-driven trading ideas across the market, explore Trending AI Robots.
Earnings Context and Why It Matters
The Pennant Group, a provider of home health, hospice, and senior living services, has been one of the more active consolidators in post-acute care. Its third quarter 2026 report followed a sizable Southeast acquisition and continued double-digit volume growth in its core areas. For investors, these results help show whether recent deals are delivering profitable scale or mainly boosting revenue. The quarter also provides insight into reimbursement trends, occupancy levels in senior living, and rising interest costs from deal financing—all factors that will influence the company's path into 2027.
Reported Results
For the third quarter ended September 30, 2026, PNTG reported total revenue of $302.3 million, a 32.0% increase from $229.0 million in the prior-year quarter. The top line came in slightly ahead of consensus estimates of roughly $299 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
GAAP diluted EPS was $0.26, up from $0.17 a year earlier, while adjusted diluted EPS was $0.35, in line with analyst expectations. Net income attributable to The Pennant Group reached $9.6 million, up 58.5% year over year. Adjusted EBITDA rose 42.4% to $24.7 million, and adjusted EBITDA before noncontrolling interest increased 44.0% to $26.1 million.
Growth was led by the Home Health and Hospice segment, where revenue climbed 38.2% to $239.8 million, supported by both acquisitions and organic admissions growth. Total home health admissions increased 39.4%, and hospice average daily census rose 34.6%. The Senior Living segment grew revenue 12.6% to $62.4 million, though average occupancy slipped to 78.4% from 80.9% in the prior-year quarter.
Market Reaction and Investor Sentiment
The third quarter print delivered a mixed message that investors are likely to weigh carefully. Revenue came in ahead of consensus and adjusted EPS matched expectations, reinforcing the company's growth narrative and acquisition integration progress. At the same time, GAAP EPS landed below some estimates, and the report highlighted a meaningful jump in net interest expense as the company financed its acquisitions, along with a decline in senior living occupancy. These factors point to margin and balance-sheet considerations that could temper enthusiasm even amid strong top-line momentum.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors should watch how PNTG converts its acquisition-driven revenue into sustainable margins. Management has indicated results were consistent with its annual guidance, which was raised earlier in 2026 to full-year revenue of $1.17 billion to $1.19 billion and EPS of $1.34 to $1.41. Continued integration of the Southeast operations remains a central theme, with remaining transition work still in progress.
Cost and financing trends also deserve attention. Net interest expense rose sharply year over year, reflecting higher borrowings tied to deal activity, and the company's leverage is worth monitoring alongside its cash-flow generation targets. On the reimbursement side, a planned home health payment increase for 2027 provides a modest tailwind after several years of cuts.
Finally, senior living occupancy will be a key swing factor. The segment's revenue continued to grow, but lower occupancy pressures near-term margins. How quickly occupancy stabilizes or recovers will influence the pace of margin expansion across the broader business.
Exploring Tickeron’s AI Screener for Earnings-Driven Ideas
In my own research process, I frequently turn to Tickeron’s AI Screener when evaluating companies like this one after earnings. It helps filter the market by technical patterns, fundamentals, trends, volatility, and AI-driven signals, allowing users to scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, and performance metrics. This approach surfaces trade ideas and breakout candidates more efficiently than manual methods, which is especially useful when tracking earnings-driven moves and building a focused watchlist.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PNTG's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PNTG turned positive on November 04, 2026. Looking at past instances where PNTG's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where PNTG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PNTG as a result. In 69 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
PNTG moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where PNTG advanced for three days, in 244 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 183 of 236 cases where PNTG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PNTG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
PNTG broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. PNTG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.282) is normal, around the industry mean (204.059). P/E Ratio (46.851) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (2.017) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (1.373) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the provision of healthcare services
Industry HospitalNursingManagement
Advertisement